Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
91 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01956669 | Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | completed | Phase 2 | 57 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 12, 2020 | clinicaltrials |
| NCT02414685 | First Line TIP in Poor Prognosis TGCTs.(TIP) | completed | Phase 2 | 19 | National Cancer Institute, SlovakiaOTHER_GOV | 1 | Aug 7, 2020 | clinicaltrials |
| NCT03493997 | Multicentre International STudy for the Prevention With Ialuril® of Radio-induced Cystitis (MISTIC)(MISTIC) | completed | Phase 2 | 100 | Study Group for Urogenital Diseases, ItalyOTHER | 4 | Jul 23, 2020 | clinicaltrials |
| NCT02443883 | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | completed | Phase 2 | 164 | Eli Lilly and CompanyINDUSTRY | 12 | Jun 29, 2020 | clinicaltrials |
| NCT00401843 | A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 307 | Janssen Research & Development, LLCINDUSTRY | 18 | Nov 19, 2019 | clinicaltrials |
| NCT02999672 | A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 4 | Aug 28, 2019 | clinicaltrials |
| NCT01367665 | STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | completed | Phase 2 | 1,232 | Hoffmann-La RocheINDUSTRY | 37 | Jun 6, 2019 | clinicaltrials |
| NCT03403777 | Avelumab in Refractory Testicular Germ Cell Cancer. | completed | Phase 2 | 8 | National Cancer Institute, SlovakiaOTHER_GOV | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02544685 | Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients(FENSY) | unknown | Phase 2 | 120 | S&D Pharma SK s.r.o.INDUSTRY | 1 | Jan 17, 2019 | clinicaltrials |
| NCT01210495 | Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma | completed | Phase 2 | 224 | PfizerINDUSTRY | 13 | Jan 9, 2019 | clinicaltrials |
| NCT00454779 | PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response | completed | Phase 2 | 113 | AmgenINDUSTRY | 9 | Oct 17, 2018 | clinicaltrials |
| NCT00500292 | A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer | completed | Phase 2 | 109 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Jan 25, 2018 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT01040832 | EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 107 | EMD SeronoINDUSTRY | 8 | Jan 30, 2017 | clinicaltrials |
| NCT02064725 | Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA | unknown | Phase 2 | 8 | Kevelt ASINDUSTRY | 5 | Jan 24, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT01715896 | A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis | completed | Phase 2 | 215 | MedImmune LLCINDUSTRY | 14 | Oct 31, 2016 | clinicaltrials |
| NCT00811135 | A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer | completed | Phase 2 | 88 | Hoffmann-La RocheINDUSTRY | 6 | Sep 29, 2016 | clinicaltrials |
| NCT00796718 | A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer | completed | Phase 2 | 62 | Hoffmann-La RocheINDUSTRY | 1 | Aug 25, 2016 | clinicaltrials |
| NCT00444587 | A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. | completed | Phase 2 | 114 | Hoffmann-La RocheINDUSTRY | 8 | Jun 21, 2016 | clinicaltrials |
| NCT00479752 | Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer(CORE 2) | completed | Phase 2 | 151 | Central European Cooperative Oncology GroupOTHER | 13 | Feb 18, 2016 | clinicaltrials |
| NCT01466231 | Everolimus in Refractory Testicular Germ Cell Cancer | completed | Phase 2 | 15 | National Cancer Institute, SlovakiaOTHER_GOV | 1 | Jan 12, 2016 | clinicaltrials |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 165 | Sesen Bio, Inc.INDUSTRY | 18 | Dec 23, 2015 | clinicaltrials |
| NCT01360840 | EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer(PERSEUS) | completed | Phase 2 | 180 | EMD SeronoINDUSTRY | 12 | Dec 14, 2015 | clinicaltrials |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)(LUCID) | terminated | Phase 2 | 627 | BiogenINDUSTRY | 23 | Oct 2, 2015 | clinicaltrials |
| NCT01121406 | BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer | completed | Phase 2 | 110 | Boehringer IngelheimINDUSTRY | 5 | Aug 13, 2015 | clinicaltrials |
| NCT01189253 | Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma | terminated | Phase 2 / Phase 3 | 133 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Aug 8, 2014 | clinicaltrials |
| NCT00297089 | A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 165 | AbbVie (prior sponsor, Abbott)INDUSTRY | 6 | Jan 31, 2013 | clinicaltrials |
| NCT00003731 | Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors | completed | Phase 2 | 39 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Sep 24, 2012 | clinicaltrials |
| NCT00027794 | Radical Prostatectomy in Treating Patients With Locally Advanced Prostate Cancer | completed | Phase 2 | 40 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Sep 24, 2012 | clinicaltrials |
| NCT00110045 | Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant | completed | Phase 2 | 171 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Sep 24, 2012 | clinicaltrials |
| NCT00041236 | Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma | completed | Phase 2 | 39 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Jul 18, 2012 | clinicaltrials |
| NCT00523159 | IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease(IMA901-202) | completed | Phase 2 | 68 | Immatics Biotechnologies GmbHINDUSTRY | 10 | Jul 10, 2012 | clinicaltrials |
| NCT00286819 | Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer | completed | Phase 2 | 50 | Central European Cooperative Oncology GroupOTHER | 4 | May 16, 2012 | clinicaltrials |
| NCT00286130 | Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 150 | Central European Cooperative Oncology GroupOTHER | 13 | May 1, 2012 | clinicaltrials |
| NCT00035100 | EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer | completed | Phase 2 | 54 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 16, 2012 | clinicaltrials |
| NCT00003643 | Combination Chemotherapy in Treating Men With Germ Cell Cancer | unknown | Phase 2 / Phase 3 | 498 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 14 | Mar 6, 2012 | clinicaltrials |
| NCT00169572 | Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy | completed | Phase 2 | 492 | GlaxoSmithKlineINDUSTRY | 19 | May 10, 2010 | clinicaltrials |
| NCT00003681 | Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome | unknown | Phase 2 | 50 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | May 12, 2009 | clinicaltrials |
| NCT00490711 | Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 7 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials